Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Egenesis

Egenesis
2014 FOUNDED
PRIVATE STATUS
1-10 EMPLOYEES
Series A LATEST DEAL TYPE
$38M LATEST DEAL AMOUNT
10 INVESTORS
Description

Developer of xenotransplantation for the benefit of human health. The company's technology helps in the transformation of xenotransplantation into a medical procedure.

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Primary Office
  • 300 Technology Square
  • Suite 301
  • Cambridge, MA 02139
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Egenesis’s full profile, request a free trial.

Egenesis Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Early Stage VC (Series A) 16-Mar-2017 $38M 0000 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Egenesis Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A 00,000,000 00.000000 00.00 00.0 00.0 00 00.0 00.000
To view this company’s complete Cap Table, request access »

Egenesis Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Synthego Venture Capital-Backed Redwood City, CA 00 00000 00000000000 00000
0000000 0000000000 Venture Capital-Backed Berkeley, CA 00 000.00 00000000000 000.00
000000000 Venture Capital-Backed Boulder, CO 00000 00000000000 00000
00000000 000000000 Corporation Cleveland, OH 0 0000000000
000000000 00000000 Venture Capital-Backed San Diego, CA 0 000.00 00000000000 000.00
To view this company’s complete list of competitors, request access »

Egenesis Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Alexandria Venture Investments Corporate Venture Capital Minority 000 0000 000000 0
Alta Partners Venture Capital Minority 000 0000 000000 0
ARCH Venture Partners Venture Capital Minority 000 0000 000000 0
Berggruen Holdings PE/Buyout Minority 000 0000 000000 0
Biomatics Capital Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 10 investors. Get the full list »

Egenesis Executive Team (3)

Name Title Board
Seat
Contact
Info
Luhan Yang Ph.D Co-Founder, President, Board Member & Chief Scientific Officer
George Church Ph.D Co-Founder & Board Member

1 Former Executive

You’re viewing 2 of 3 executives. Get the full list »

Egenesis Board Members (4)

Name Representing Role Since Contact
Info
Boris Nikolic MD Biomatics Capital Board Member 000 0000
Daniel Lynch Self Chairman 000 0000
George Church Ph.D Self Co-Founder & Board Member 000 0000
Steven Gillis Ph.D ARCH Venture Partners Board Member 000 0000